Akebia Ther
$ 1.56
6.12%
14 Apr - close price
- Market Cap 417,892,000 USD
- Current Price $ 1.56
- High / Low $ 1.56 / 1.47
- Stock P/E N/A
- Book Value 0.12
- EPS -0.02
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE -5.53 %
- 52 Week High 4.08
- 52 Week Low 1.14
About
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$4.40
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-12 | 2025-11-10 | 2025-08-07 | 2025-05-07 | 2025-03-12 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-03-14 | 2023-11-08 | 2023-08-25 | 2023-05-08 |
| Reported EPS | -0.05 | 0.002 | 0.0267 | 0.0247 | -0.1 | -0.1 | -0.04 | -0.09 | 0.0032 | -0.08 | -0.06 | -0.14 |
| Estimated EPS | 0.002 | -0.04 | -0.02 | -0.08 | -0.075 | -0.06 | -0.05 | -0.08 | -0.04 | -0.08 | -0.02 | -0.15 |
| Surprise | -0.052 | 0.042 | 0.0467 | 0.1047 | -0.025 | -0.04 | 0.01 | -0.01 | 0.0432 | 0 | -0.04 | 0.01 |
| Surprise Percentage | -2600% | 105% | 233.5% | 130.875% | -33.3333% | -66.6667% | 20% | -12.5% | 108% | 0% | -200% | 6.6667% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.01 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AKBA
2026-04-15 08:40:13
Akebia Therapeutics (NASDAQ:AKBA) has received a consensus "Moderate Buy" rating from six brokerages, with an average 12-month price target of $5.25. The company's shares recently rose 6.1% to $1.56, with a market cap of $417.9 million, after reporting a quarterly loss of $0.05 per share (missing estimates) but exceeding revenue expectations with $57.6 million. Insider and institutional activity shows CEO John Butler acquiring shares, while significant institutional investors like Goldman Sachs and JPMorgan increased their holdings.
2026-04-14 11:40:13
Akebia Therapeutics has announced that the first participants have been dosed in a Phase 1 clinical trial for AKB-9090, an internally developed HIF-PH inhibitor. The drug is being evaluated as a potential treatment for cardiac surgery-associated acute kidney injury, with top-line data expected in early 2027. This development is part of Akebia's broader pipeline of kidney disease programs, which also includes praliciguat for focal segmental glomerulosclerosis and AKB-097 for rare kidney diseases.
2026-04-13 23:38:55
This article highlights three promising penny stocks in the U.S. market: Akebia Therapeutics (AKBA), SNDL (SNDL), and Treace Medical Concepts (TMCI). While penny stocks carry risks, these companies are noted for their potential based on recent financial performance, strategic developments, and market positions. The U.S. market itself shows robust growth, providing a favorable context for such investment opportunities.
2026-04-13 12:10:06
Akebia Therapeutics has announced that the first participants have been dosed in a Phase 1 clinical trial for AKB-9090, a hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor designed to treat cardiac surgery-associated acute kidney injury (AKI). The trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AKB-9090 in healthy adults, with top-line data expected in early 2027. This drug is part of Akebia's broader pipeline of kidney disease programs, which also includes praliciguat and AKB-097.
2026-04-13 12:09:17
Akebia Therapeutics has dosed the first participants in a Phase 1 clinical trial of AKB-9090, an IV HIF-PH inhibitor for cardiac surgery-associated acute kidney injury (AKI). The study aims to enroll up to 70 participants to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, with topline data expected in early 2027. This advancement further expands Akebia's kidney-focused pipeline, which also includes praliciguat and AKB-097.
2026-04-13 12:09:17
Akebia Therapeutics announced that the first participants have been dosed in a Phase 1 clinical trial of AKB-9090, a hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor. AKB-9090 is being evaluated as a potential treatment for cardiac surgery-associated acute kidney injury, with top-line data expected in early 2027. The company is also developing praliciguat for focal segmental glomerulosclerosis and AKB-097 for rare kidney diseases.
